NCT04225390 2026-02-10
PROMIT
University of Erlangen-Nürnberg Medical School
Phase 2 Completed
Clinical Trials
35 trialsNCT03159897 2025-08-08
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT03331341 2025-08-05
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Phase 1/2 Completed
NCT03430297 2024-09-19
JS001
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT00678327 2024-05-08
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London
Phase 3 Completed
NCT01359956 2023-04-11
SICOG 0109
National Cancer Institute, Naples
Phase 3 Completed
NCT02292979 2022-08-19
BREACH
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT01132807 2021-06-14
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02505269 2020-08-24
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT00498979 2020-07-24
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01356680 2020-04-06
HD17 for Intermediate Stage Hodgkin Lymphoma
University of Cologne
Phase 3 Completed
NCT00416832 2020-03-26
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Completed
NCT00433459 2020-03-26
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
Phase 3 Completed
NCT01551459 2019-10-29
SUAVE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00038558 2018-10-31
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01569204 2018-10-29
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
University of Cologne
Phase 2 Completed
NCT00369681 2018-08-27
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01056679 2018-03-22
AVD-Rev
University of Cologne
Phase 1 Completed
NCT01534078 2018-02-20
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT00802880 2017-02-13
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT00580320 2016-08-18
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Virginia Commonwealth University
Phase 1 Completed
NCT00412581 2016-04-29
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00837148 2015-11-20
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01376713 2015-10-06
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Medical University of Vienna
Phase 2 Completed
NCT01251107 2015-08-13
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
Fondazione Michelangelo
Phase 3 Completed
NCT00597038 2013-12-16
A Phase I/II Study of Dasatinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00504504 2013-07-09
Rituximab and ABVD for Hodgkin's Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01404936 2013-02-01
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002882 2011-12-13
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00794235 2010-01-08
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
University of Zurich
Phase 2 Completed
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed
NCT00559026 2007-11-16
DTIC-melvacc
Istituto Superiore di SanitÃ
Phase 1 Completed